摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-aminopyrimidin-4-yl)-7-bromo-6-fluoro-1,3benzodiazol-4-amine | 1394121-33-5

中文名称
——
中文别名
——
英文名称
3-(2-aminopyrimidin-4-yl)-7-bromo-6-fluoro-1,3benzodiazol-4-amine
英文别名
3-(2-aminopyrimidin-4-yl)-7-bromo-6-fluorobenzimidazol-4-amine
3-(2-aminopyrimidin-4-yl)-7-bromo-6-fluoro-1,3benzodiazol-4-amine化学式
CAS
1394121-33-5
化学式
C11H8BrFN6
mdl
——
分子量
323.127
InChiKey
HDWDWEMVIRAHCZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    95.6
  • 氢给体数:
    2
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    3-(2-aminopyrimidin-4-yl)-7-bromo-6-fluoro-1,3benzodiazol-4-amine2-甲基-3-丁炔-2-醇copper(l) iodide四(三苯基膦)钯 哌啶 作用下, 反应 2.5h, 以26.7%的产率得到4-[3-(2-aminopyrimidin-4-yl)-6-fluoro-1,3-benzodiazol-5-yl]-2-methylbut-3-yn-2-ol
    参考文献:
    名称:
    6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR
    摘要:
    这项发明涉及公式I的新化合物: 其中A、Y、R1、R2和下标b各自具有如本文所述的含义,以及公式I的化合物、立体异构体、几何异构体、互变异构体、溶剂合物、代谢物、同位素、药学上可接受的盐或其前药。公式I的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度激活的疾病和紊乱中是有用的。
    公开号:
    US20120214762A1
点击查看最新优质反应信息

文献信息

  • 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor
    申请人:Genentech, Inc.
    公开号:US20150038460A1
    公开(公告)日:2015-02-05
    The invention relates to novel compounds of Formula I: wherein A, Y, R 1 , R 2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
    该发明涉及公式I的新化合物:其中A,Y,R1,R2和下标b各自具有如下所述的含义,以及公式I的化合物,立体异构体,几何异构体,互变异构体,溶剂化物,代谢物,同位素,药学上可接受的盐或其前药。公式I的化合物及其制药组合物在治疗疾病和障碍方面有用,其中观察到NF-kB信号不良或过度激活。
  • 6,5-heterocyclic propargylic alcohol compounds and uses therefor
    申请人:Staben Steven
    公开号:US08901313B2
    公开(公告)日:2014-12-02
    The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
    本发明涉及一种新型化合物I的公式:其中A,Y,R1,R2和下标b具有如下所述的含义,以及化合物I的立体异构体,几何异构体,互变异构体,溶剂化物,代谢物,同位素,药学上可接受的盐或其前药。公式I化合物及其制药组合物在治疗疾病和障碍方面有用,其中观察到NF-kB信号的不良或过度激活。
  • US8901313B2
    申请人:——
    公开号:US8901313B2
    公开(公告)日:2014-12-02
  • [EN] 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR<br/>[FR] COMPOSÉS D'ALCOOL PROPARGYLIQUE 6,5-HÉTÉROCYCLIQUES ET UTILISATIONS DE CEUX-CI
    申请人:HOFFMANN LA ROCHE
    公开号:WO2012123522A1
    公开(公告)日:2012-09-20
    The invention relates to novel compounds of Formula (I) wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
  • 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR
    申请人:Staben Steven
    公开号:US20120214762A1
    公开(公告)日:2012-08-23
    The invention relates to novel compounds of Formula I: wherein A, Y, R 1 , R 2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
    这项发明涉及公式I的新化合物: 其中A、Y、R1、R2和下标b各自具有如本文所述的含义,以及公式I的化合物、立体异构体、几何异构体、互变异构体、溶剂合物、代谢物、同位素、药学上可接受的盐或其前药。公式I的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度激活的疾病和紊乱中是有用的。
查看更多